MabVax Therapeutics - "Introducing MabVax Therapeutics: Newly Public Company Achieves Multiple Milestones in Recent Quarter"
ACCESSWIRE - Thu Oct 23, 7:16AM CDT
New York, NY / ACCESSWIRE / October 23, 2014 / MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX) today published a new blog post on The Chairman's Blog, written by the Company's President and Chief Executive Officer, David Hansen. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
MabVax Therapeutics Launches Online Corporate Communication Channels and New Website
PR Newswire - Thu Oct 23, 7:00AM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical stage oncology drug development company, announced today a suite of online corporate communication channels to maintain on-going direct communication with shareholders and other interested parties. The Company has launched official portals on social media channels including Facebook, Twitter, LinkedIn, Google+, and The Chairman's Blog.
MabVax Therapeutics Nominates The Fully Human Antibody HuMab 5B1 As The Company's Lead Clinical Development Candidate
PR Newswire - Tue Oct 21, 8:00AM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX) a clinical stage oncology drug development company, announced today that it has formally nominated its HuMab 5B1 antibody as a clinical candidate for the diagnosis and treatment of pancreatic and colon cancer. The fully human antibody, recovered from patients undergoing cancer vaccine treatment at Memorial Sloan-Kettering Cancer Center, has entered GMP manufacturing to produce clinical trial supplies for a planned Phase 1 program to begin in the second half of 2015. The development plan calls for dual Phase 1 clinical trials to take place simultaneously. One program will be aimed at demonstrating the utility of the radio-labeled antibody as a novel PET imaging agent for the diagnosis and management of pancreatic cancer. The second program will determine the safety and potential utility of the full-length antibody as a treatment for the same cancer.
MabVax Therapeutics reports change in common stock ticker symbol
M2 - Mon Oct 13, 8:30AM CDT
Oncology company MabVax Therapeutics Holdings said on Friday that its common shares will commence trading under the new trading symbol MBVX (OTCQB:MBVX.).